Medtronic (MDT) completed the previously-announced acquisition of Mazor Robotics, a transaction valued at US $1.7BB (or $1.3BB net MDT’s existing stake in Mazor and cash acquired). Mazor joins MDT’s Neurosurgery business, part of the Restorative Therapies Group’s Brain Therapies division.
This transaction combines MDT’s spinal implants, navigation and 3D imaging tools with Mazor’s robotic-assisted surgery systems, for example in the co-developed Mazor X™ Stealth Edition, which is now FDA-cleared.
MDT projects the acquisition will generate a double-digit return on invested capital by year four, with an increasing contribution thereafter.
Medtronic (MDT) completed the previously-announced acquisition of Mazor Robotics, a transaction valued at US $1.7BB (or $1.3BB net MDT's existing stake in Mazor and cash acquired). Mazor joins MDT's Neurosurgery business, part of the Restorative Therapies Group's Brain Therapies division.
This transaction combines MDT's spinal implants,...
Medtronic (MDT) completed the previously-announced acquisition of Mazor Robotics, a transaction valued at US $1.7BB (or $1.3BB net MDT’s existing stake in Mazor and cash acquired). Mazor joins MDT’s Neurosurgery business, part of the Restorative Therapies Group’s Brain Therapies division.
This transaction combines MDT’s spinal implants, navigation and 3D imaging tools with Mazor’s robotic-assisted surgery systems, for example in the co-developed Mazor X™ Stealth Edition, which is now FDA-cleared.
MDT projects the acquisition will generate a double-digit return on invested capital by year four, with an increasing contribution thereafter.
Copy to clipboard 
